>Innovation Lab Capabilities
In our efforts to provide the right blend of innovation and value to our clients, ACROBiosystems has NEW Lab Services! Our scientists have implemented and mastered numerous assay platforms over the years. Our recent introduction of the INNOVATION LAB offers TCR Screening Technology and the MSD SQ120 into our assay development portfolio.
ACROBiosystems offers an array of MSD-based immunoassays with a proven increase in both dynamic range and sensitivity, made possible through electro chemiluminescent labeling. ACROBiosystems utilizes our expertise to accurately access clients’ needs and to guide in the design of assays more sensitive than traditional ELISA.
Using electrochemiluminescently-labeled detection antibodies, the MSD-ECL platform detects excitation near electrodes located in the bottom of each microplate. As electricity is applied to the plate electrodes, the electrochemiluminescent labels are stimulated to emit light. The intensity of those emissions is then converted to a quantitative measurement of the target analytes in cell supernatant, serum, plasma or whole blood.
The MSD-ECL platform offers great flexibility with stable, non-radioactive, and easily conjugated labels. Because of these factors, this technology can be applied to all types of traditional ELISAs, such as direct, indirect, sandwich or competitive assays at an increased sensitivity level that can detect samples with concentrations as low as 0.1pg/mL.
We have also found MSD assays are optimal for complex matrices as they typically yield low interference from components like serum or plasma. MSD is particularly advantageous in that its bridging formats are not specific for species or antibody subclass.
Meso Scale Discovery (MSD-ECL) can be applied in our work with biomarker screening, immunogenicity, pharmacokinetics (PK) and cell-based assays.
MSD’s proprietary multi-array technology can provide significantly increased sensitivity and dynamic range over standard ELISA with the added benefit of multiplexing. Fast, yet continuous, non-destructive reads produce consistent assay data with low sample volume requirements and minimal reagent consumption. An added benefit of the electrochemiluminescence (ECL) detection technology is that it reduces assay background by separating the excitation mechanism from the signal.
With a broad range of quantitation, assays conducted using MSD technology are cost-effective and exhibit a reduced need for repeats stemming from readings above the ULOQ or below the LLOQ. This means more valid data points from sample sets in a single run than with other similar platforms.
The combination of rapid read times and the ability to perform multiple, simultaneous tests on a single sample increases productivity, conserves sample, and delivers results quickly.
ACROBiosystems’s scientists have particular expertise using MSD-ECL for complex matrices and have had proven success meeting the demands of even the most challenging bioanalytical assays. Let us show you how increased sensitivity and reduced sample requirements can open new possibilities in your studies today.
With our high-throughput sequencing and T-cell receptor repertoire analysis technology, our TCR screening service can help you dynamically visualize repertoire diversity and testng across diﬀerent sequencing samples.
Based on our Quantitative Real-time PCR (q-PCR) platform, ACROBiosystems offers RNA/DNA analysis options to help expedite your research. We offer a full range of sample analysis options from isolation and quantitation up to sequencing. Our quantitative PCR platform produces highly specific and reproducible results. We specialize in T cell analysis and offer other customized analysis options for client needs.
This web search service is supported by Google Inc.